GlassScriptPhysician profile
Rakhi Kheraj
NPI 1376708586
$5,929.26
in general payments reported to CMS, 2019-2025
37 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $153 · 2021: $630 · 2022: $1,381 · 2023: $2,454 · 2024: $586 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069 · Travel and Lodging: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,069.20 |
| Travel and Lodging | $1,113.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,946.41 | 2019-2023 | Orise |
| Abbvie INC. | $1,326.23 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $820.26 | 2019-2023 | Trulance, Xifaxan, Plenvu |
| Ironwood Pharmaceuticals, INC | $155.69 | 2021-2023 | Linzess |
| Madrigal Pharmaceuticals | $143.09 | 2025 | Rezdiffra |
| Ge Healthcare | $135.19 | 2019 | |
| Braintree Laboratories, INC. | $110.47 | 2021-2023 | Sutab |
| Astrazeneca Pharmaceuticals LP | $109.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $107.57 | 2023 | Dupixent |
| Sunovion Pharmaceuticals INC. | $97.59 | 2019 | |
| Gilead Sciences, INC. | $92.32 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $91.29 | 2023-2024 | Terlivaz |
| Genzyme Corporation | $87.41 | 2023-2024 | |
| Pfizer INC. | $76.59 | 2023-2024 | |
| Insulet Corporation | $69.19 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $51.55 | 2022-2023 | Vyvgart |
| Amgen INC. | $44.18 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $43.10 | 2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $42.24 | 2024 | Voquezna |
| Lilly USA, LLC | $38.53 | 2024 | Omvoh, Emgality |
| Nestle Healthcare Nutrition INC. | $37.47 | 2022-2023 | |
| Sk Life Science, INC. | $33.91 | 2023 | |
| Merck Sharp & Dohme LLC | $26.68 | 2024 | Dificid |
| Novo Nordisk INC | $24.98 | 2020 | |
| Celgene Corporation | $20.22 | 2023 | Zeposia |
| Janssen Biotech, INC. | $20.09 | 2021 | |
| Abbott Laboratories | $19.44 | 2022 | |
| Romark Laboratories, Lc | $19.05 | 2019-2020 | |
| Alfasigma USA, INC. | $18.23 | 2020 | |
| Allergan, INC. | $17.91 | 2019 | |
| Eisai INC. | $17.48 | 2023 | |
| Medtronic, INC. | $15.87 | 2023 | Venaseal |
| Corcept Therapeutics | $15.34 | 2020 | |
| Kyowa Kirin, INC. | $15.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.75 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakhi Kheraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.